Reviews

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: Compounded medications are not FDA-approved finished drug products. Gala GLP-1 connects patients with licensed healthcare providers who independently evaluate eligibility for treatment. No prescription is designed to deliver. Always consult a qualified healthcare professional before starting any prescription treatment. This article is produced by the TotalCareMedical.com editorial team for informational purposes only and does not constitute medical advice.

What Is Gala GLP-1?

Gala GLP-1 is a telehealth platform operated by AI Coaching, Inc. that connects patients across all 50 states with licensed healthcare providers for GLP-1 and GLP-1/GIP weight management consultations. The platform facilitates access to compounded prescription medications without requiring insurance, with pricing starting at $179 per month on a 3-month plan. Prescriptions are issued only when a licensed provider determines treatment is medically appropriate after reviewing each patient's health information.

The platform positions itself around affordability and access. Brand-name GLP-1 medications — Wegovy, Ozempic, Mounjaro, Zepbound — carry monthly costs that frequently exceed $1,000 without insurance. Gala's compounded alternative targets a meaningfully lower price point, though the regulatory and quality implications of that difference are ones any prospective patient should understand before committing.

Medical services through the platform are provided by licensed physicians and clinicians affiliated with independently owned and operated medical practices, including OpenLoop-affiliated medical groups. Gala itself provides administrative, technology, and management services and does not practice medicine directly.

What Medications Does Gala Offer?

Gala GLP-1's primary offering is a compounded GLP-1/GIP medication — tirzepatide is the GLP-1/GIP dual agonist referenced in this category. A Microdosing GLP-1/GIP option is also available. The platform additionally lists brand-name Ozempic (semaglutide from Novo Nordisk) and notes that an oral GLP-1 option is coming soon.

The distinction between compounded and FDA-approved medications matters in this category and is worth stating precisely. Compounded GLP-1 medications are prepared by licensed compounding pharmacies using active pharmaceutical ingredients sourced from FDA-regulated suppliers. The finished compounded product is not reviewed or approved by the FDA for safety, quality, or efficacy. A licensed provider prescribes compounded medications when commercially available options are not suitable for a given patient. Gala GLP-1 discloses this on its homepage.

The regulatory landscape for compounded GLP-1 medications has shifted materially since 2024. The FDA removed tirzepatide from its national drug shortage list in December 2024 and removed semaglutide in February 2025. These shortage designations had formed the primary legal basis for widespread GLP-1 compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. With the shortages resolved, the FDA has pursued enforcement action against compounders producing products that are essentially copies of commercially available drugs. A proposed rule published in 2026 would bar 503B outsourcing facilities from bulk compounding of semaglutide, tirzepatide, and liraglutide entirely; the public comment period on that proposal runs through June 29, 2026. Licensed 503A pharmacies may still produce non-copy formulations with documented medical necessity under applicable regulations. Patients currently on or considering compounded GLP-1 therapy should confirm the regulatory status and pharmacy sourcing with any platform before subscribing.

Gala GLP-1's official materials state that medications are sourced from “a wide network of pharmacies across all 50 states.” The platform does not publicly disclose whether partner pharmacies operate as 503A compounders or 503B outsourcing facilities. That distinction affects the regulatory oversight level applied to the compounded product. Prospective patients should ask the platform directly before enrolling.

Pricing: What Has Been Verified

The official Gala GLP-1 website references pricing at two points: $179 per month on a 3-month plan and $199 per month as the standard monthly rate. Both figures appear in official platform materials, suggesting pricing may vary by plan structure or may have been updated at different points in the site's content. The 3-month subscription figures that have been independently verified are: standard GLP-1/GIP plan at $179 per month ($597 total) and Microdosing GLP-1/GIP at $149 per month ($447 total). Final pricing is confirmed at checkout. Verify current pricing directly at galaglp1.com before subscribing, as plan structure can affect what you pay.

The subscription is represented as all-inclusive: provider consultations, medication, dosage adjustments, and ongoing asynchronous provider messaging are covered under the single monthly fee. If a higher dose is recommended during treatment, it is stated to be available at no additional cost — which is a material differentiator in a category where some platforms charge more at higher doses.

No insurance is required. The platform does not process insurance claims.

How the Process Works

Prospective patients begin with an online health assessment that collects medical history, current medications, lifestyle factors, and weight management goals. A licensed healthcare provider affiliated with OpenLoop-affiliated or other partner medical practices reviews the submitted information and determines whether GLP-1 treatment is medically appropriate. No specific medication or prescription is designed to deliver.

Depending on the patient's location, applicable state law, and the type of medication under consideration, the initial consultation may be conducted via synchronous video visit or through asynchronous online messaging. If a video visit is required, it typically occurs at the initial consultation only. Ongoing follow-ups, dosage adjustments, and questions are handled through the platform's messaging system.

If treatment is prescribed, the prescription is fulfilled by a partner pharmacy from Gala's pharmacy network and shipped directly to the patient. Gala GLP-1 offers a mobile application for tracking.

Refund and Cancellation Policy

Gala GLP-1 does not appear to offer a standard money-back guarantee based on information available from third-party review sources. Refund and cancellation terms are not prominently detailed on the platform homepage. Before subscribing, particularly to a multi-month plan, review the current refund and cancellation policy directly at galaglp1.com. Pay attention to billing cycle terms — some users in third-party reviews have reported confusion around charges and cancellation timing.

What the Editorial Team Found in Third-Party Reviews

TotalCareMedical.com does not publish testimonials or aggregate star ratings as a substitute for evidence-based analysis. What third-party review data informs is the pattern of patient-reported experiences, which is useful context alongside the platform's stated features. Positive patterns in third-party reviews include straightforward onboarding, app usability, competitive pricing relative to other telehealth GLP-1 providers, and responsive customer service in the majority of reports. Negative patterns include reports of difficulty escalating dosing, difficulty reaching support at some points, and at least one report of being charged for a full multi-month plan at a lower starting dose than the patient had specified based on prior GLP-1 use. These are not universal experiences, and individual results with any telehealth platform depend heavily on provider decisions specific to each patient's clinical profile.

The editorial team does not characterize patient experiences with language that implies certainty about efficacy or safety for any individual reader. Every patient's eligibility, dosing trajectory, and outcome is determined by a licensed provider reviewing that patient's specific health information.

Who Is Gala GLP-1 Designed For?

GLP-1 medications are typically prescribed for adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or sleep apnea. Final eligibility is determined by a licensed provider after reviewing each individual's health information. Gala GLP-1's platform is designed as a cash-pay, no-insurance-required pathway — it may be particularly relevant for individuals who have been priced out of brand-name GLP-1 options or who lack insurance coverage for weight management medications.

Individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis history, or certain other contraindicated conditions are not appropriate candidates for GLP-1 therapy and should discuss their full medical history with a licensed provider before any telehealth evaluation.

Editorial Assessment

Gala GLP-1 operates within the compounded GLP-1 telehealth category at one of the lower advertised price points in the market. The platform's disclosed structure — licensed providers through OpenLoop-affiliated practices, pharmacy network covering all 50 states, all-inclusive pricing with no dose-escalation cost penalties — is consistent with legitimate telehealth weight management platforms in this category. The compounded medication disclosure on the platform's homepage is present and accurate.

Three areas warrant independent verification before subscribing. First, confirm the current regulatory status of the platform's pharmacy partners and whether they operate as 503A or 503B facilities, given the active enforcement environment for compounded GLP-1 in 2026. Second, verify the current pricing at checkout — official materials reference both $179 and $199 per month, and the figure applicable to your plan should be confirmed before payment. Third, review the refund and cancellation terms carefully before committing to a multi-month subscription.

For readers evaluating other telehealth GLP-1 options, the editorial team has also reviewed SynergyRx GLP-1 Weight Loss, TrimRx GLP-1, and Embody GLP-1, among others. Understanding how multiple platforms compare on pharmacy sourcing, pricing structure, and provider access helps in forming an accurate picture of what each offers.

For a detailed look at the side effects and safety considerations associated with compounded GLP-1 therapy through platforms like Gala, see the editorial team's analysis: Gala GLP-1 Side Effects: What the Clinical Literature Shows.

For a breakdown of how Gala GLP-1's pricing compares to competing platforms, see: Gala GLP-1 Cost Analysis: What You Actually Pay vs. Competitors.

Frequently Asked Questions

Is Gala GLP-1 FDA-approved?

No. Gala GLP-1 provides access to compounded GLP-1 and GLP-1/GIP medications, which are not FDA-approved finished drug products. Compounded medications are prepared by licensed pharmacies under individual prescriptions. A licensed healthcare provider evaluates each patient and prescribes treatment when medically appropriate.

How much does Gala GLP-1 cost?

According to official Gala GLP-1 materials, the standard compounded GLP-1/GIP plan starts at $179 per month on a 3-month subscription ($597 total). The Microdosing GLP-1/GIP plan is $149 per month on a 3-month plan ($447 total). Final pricing is confirmed at checkout. Verify current pricing at galaglp1.com before subscribing.

Does Gala GLP-1 require insurance?

No. Gala GLP-1 operates as a cash-pay platform with no insurance requirement. Pricing is subscription-based and covers provider consultations, medication, dosage adjustments, and ongoing provider messaging.

What medications does Gala GLP-1 offer?

Gala GLP-1 offers compounded GLP-1/GIP medication (tirzepatide is the primary GLP-1/GIP dual agonist in this category), a Microdosing GLP-1/GIP option, and brand-name Ozempic. An oral GLP-1 option is listed as coming soon. Compounded medications are not FDA-approved. A licensed provider determines what is appropriate for each patient.

Is a video visit required to start Gala GLP-1?

Not always. Depending on the patient, state law, and medication type, consultations may be conducted via synchronous video visit or asynchronously through online messaging. If a video visit is required, it typically occurs at the initial consultation. Follow-ups are handled through the platform's messaging system.

By TotalCareMedical.com Health Team

Editorial notice: TotalCareMedical.com is an independent health and wellness research publication. This comparison is for educational and informational purposes only and does not constitute medical advice or a recommendation for any specific program. GLP-1 medications are prescription drugs. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. All pricing and program details are based on publicly available information at the time of publication and are subject to change — verify directly with each platform before enrolling. Some links on this page may be affiliate links; see our disclosure for details.

Comparing GLP-1 Telehealth Programs: What Actually Matters

The compounded GLP-1 telehealth market has expanded significantly heading into 2026, and the number of platforms offering virtual GLP-1 programs has made program comparison increasingly relevant for patients doing due diligence before enrolling. This comparison evaluates Wellorithm against other programs reviewed on this site — TeleHealth Med and SynergyRx GLP-1 Weight Loss — on the dimensions that most affect the patient experience: pricing structure, medication options, pharmacy sourcing, refund policy, clinical intake, and what each program includes.

For the full independent review of Wellorithm's program terms and structure, see our Wellorithm review. For the full index of telehealth platform reviews on this site, visit the telehealth platform reviews hub.

The Comparison Framework

Before comparing platforms, it is worth establishing what the comparison is and is not. This is a comparison of published program terms and structures — not a clinical efficacy comparison. The GLP-1 medications (semaglutide and tirzepatide) are the same active ingredients across all compounded programs. Clinical outcomes depend on the medication class itself, the dose prescribed and titrated, patient adherence, and lifestyle factors — not on which telehealth platform facilitated the prescription. Choosing the right platform is about access, cost structure, clinical process quality, and consumer protection terms — not about the medication performing differently based on where you enrolled.

Wellorithm: Program Summary

Wellorithm is a telehealth platform connecting patients with licensed clinicians for compounded GLP-1 evaluation. The program offers compounded semaglutide (injection and oral dissolving tablets) and compounded tirzepatide (injection and oral dissolving tablets). All medications are compounded formulations — not FDA-approved brand-name products. According to the official website, published starting prices are $147 for compounded semaglutide and $249 for compounded tirzepatide. Membership is billed on a 28-day recurring cycle. Payments are non-refundable once processed; cancellation is available at any time by contacting support via email. The platform serves 49 states (Louisiana excluded). Support is available 24/7 at +1 (877) 402-6778. The program operates on a cash-pay basis — insurance is generally not billed directly.

TeleHealth Med: Program Summary

TeleHealth Med is a compounded GLP-1 telehealth program that connects patients with licensed providers for online consultation, prescription, and home medication delivery through licensed U.S. pharmacies. The program's published starting price is $147. Its model follows the same three-entity structure as Wellorithm: platform, independent licensed clinicians, and pharmacy partners. The program is described as offering personalized treatment plans, 24/7 support, and flexible video consultation scheduling. As with Wellorithm, compounded medications offered through TeleHealth Med have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

SynergyRx GLP-1 Weight Loss: Program Summary

SynergyRx GLP-1 Weight Loss distinguishes itself from Wellorithm and TeleHealth Med primarily by offering both compounded GLP-1 options and FDA-approved brand-name medications — Wegovy, Ozempic, and Mounjaro — for patients for whom brand-name products are clinically appropriate. Published starting prices for SynergyRx are higher across the compounded tier: compounded semaglutide injection from $199, compounded tirzepatide injection from $349, oral compounded semaglutide from $299, oral compounded tirzepatide from $399. Brand-name options start at $499 (Ozempic) or $947 (Wegovy, Mounjaro). The program names its medical team (Lion MD, led by Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD) and pharmacy partners (Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx), providing a level of sourcing transparency that patients evaluating compounded medication programs may find relevant. The program is available in all 50 states per its published FAQ.

Head-to-Head: Key Comparison Dimensions

Pricing for compounded semaglutide: Wellorithm from $147, TeleHealth Med from $147, SynergyRx from $199. All are starting prices subject to dose and plan. Wellorithm and TeleHealth Med are at price parity on the published entry price for this medication.

Pricing for compounded tirzepatide: Wellorithm from $249, SynergyRx from $349. TeleHealth Med's tirzepatide pricing was not separately published in available materials at the time of this review — verify directly with the platform.

Medication scope: Wellorithm and TeleHealth Med offer compounded formulations only. SynergyRx offers both compounded and FDA-approved brand-name options, making it the only platform of the three with a pathway to Wegovy, Ozempic, or Mounjaro for patients who qualify and for whom the cost is accessible.

Pharmacy sourcing transparency: SynergyRx names its pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx). Wellorithm refers to “trusted U.S. pharmacies” without naming partners in publicly available materials. TeleHealth Med similarly references licensed U.S. pharmacy partners. For patients who want to independently verify the compounding compliance status of the dispensing pharmacy, named partners provide a research pathway that unnamed references do not.

Refund terms: Wellorithm's published terms state payments are non-refundable once processed. SynergyRx and TeleHealth Med refund policies should be verified directly with each platform — terms vary across the category and are subject to change.

State coverage: Wellorithm serves 49 states (Louisiana excluded). SynergyRx is published as available in all 50 states. Verify your state's current availability with each platform before enrolling.

Clinical intake depth: All three programs require a digital health questionnaire and clinician evaluation before prescribing. SynergyRx's published clinical description is the most detailed of the three — it specifies eligibility criteria (BMI ≥30 or ≥27 with comorbidity), names the medical team, and details the titration approach. Wellorithm's published intake description (2-minute quiz) is less detailed about clinical evaluation depth — this is worth confirming directly with the platform for patients who want to understand the thoroughness of the screening process. For a deeper dive, see Oak Longevity Review: Is the GLP-1 Pricing Real?.

How to Choose: Questions Worth Asking

The right program is the one that fits your health profile, budget, state, and preferences for medication type and clinical process depth. These are the questions worth asking before enrolling in any of these programs.

Do you want access to FDA-approved brand-name medications if compounded options become unavailable or if your clinician recommends them? If yes, SynergyRx is the only platform of the three with that pathway published. Is price the primary constraint? Wellorithm and TeleHealth Med offer the lowest published starting prices in this comparison. Do you want to know which pharmacy will dispense your medication so you can independently verify its compounding compliance status? SynergyRx provides named pharmacy partners. Is state availability a factor — are you in Louisiana? Only SynergyRx publishes 50-state availability among the three platforms reviewed here. What is the refund policy if you are not approved for a prescription or decide not to proceed after enrollment? This should be confirmed in writing before providing payment information to any platform.

Frequently Asked Questions

How does Wellorithm compare to other GLP-1 telehealth programs on price? Wellorithm's published starting prices — $147 for compounded semaglutide, $249 for compounded tirzepatide — are at the lower end of published pricing in the compounded GLP-1 telehealth category. Actual costs depend on dosage and plan. Comparable platforms in this category publish semaglutide starting prices ranging from $147 to $350 or higher, with tirzepatide priced above semaglutide across the category. Price comparisons should account for what is included: consultation fees, monitoring, and pharmacy sourcing vary by platform.

What makes Wellorithm different from SynergyRx? SynergyRx offers both compounded and FDA-approved brand-name GLP-1 options, including Wegovy, Ozempic, and Mounjaro, with named pharmacy partners and a named medical team. Wellorithm focuses on compounded formulations only, at lower published starting prices, with 24/7 support access. Both are cash-pay programs. The right choice depends on whether brand-name medication access matters to you and what total cost structure fits your situation.

Which GLP-1 telehealth platform is best? No single platform is universally best. The right program depends on individual health profile, budget, medication preference (compounded vs. brand-name), state availability, and the clinical intake process. The most important evaluation dimensions are: whether the clinician evaluation is thorough, what pharmacy dispenses the medication and what its compounding compliance status is, what follow-up monitoring is included, and what the refund and cancellation terms are.

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important notice: This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that must be evaluated, prescribed, and monitored by a licensed healthcare professional. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Eligibility for any prescription program is determined solely by a licensed clinician. Always consult your healthcare provider before starting any medication or weight management program.

What Is Wellorithm?

Wellorithm is a telehealth weight management platform that connects patients with licensed U.S. clinicians for evaluation and, when medically appropriate, prescription access to compounded GLP-1 medications. The platform does not dispense medication itself — it coordinates between an independent clinical layer and licensed U.S. pharmacy partners, a three-entity structure standard across telehealth weight management services.

Understanding that structure matters before evaluating any telehealth program. Wellorithm is the technology platform. Clinical decisions belong to the independent licensed providers. Medication is dispensed by licensed compounding pharmacies. These are three distinct functions, and each operates under its own regulatory framework.

For a broader overview of how GLP-1 telehealth platforms are structured and evaluated, see our telehealth platform reviews index, which covers multiple programs in this category. For a full review of Wellorithm's pricing, refund policy, and program terms, see our Wellorithm review.

The Compounding Distinction: What It Means for Patients

Wellorithm's program centers on compounded GLP-1 medications. This distinction carries specific regulatory and clinical implications that every prospective patient should understand before enrolling.

Semaglutide is the active ingredient in FDA-approved brand-name products including Wegovy and Ozempic. Tirzepatide is the active ingredient in FDA-approved products including Mounjaro and Zepbound. The compounded versions available through platforms like Wellorithm are prepared by licensed compounding pharmacies based on individual prescriptions — but the finished compounded product has not undergone the same FDA approval process as the brand-name drugs.

As Wellorithm's own website states: compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. The prescribing clinician makes the determination of whether a compounded option is appropriate for each individual patient.

The legal landscape for compounded GLP-1 medications has also been directly tied to FDA drug shortage designations. Federal compounding regulations restrict the production of compounded drugs that are essentially a copy of commercially available FDA-approved products, and enforcement discretion tied to GLP-1 shortage status has been an active and evolving area for semaglutide and tirzepatide specifically. The availability of compounded GLP-1 medications through any telehealth platform can change depending on current FDA shortage designation — confirm current availability directly with Wellorithm before enrolling.

How the Wellorithm Process Works

Wellorithm describes a four-stage process for patients moving from inquiry to treatment. Each stage involves a distinct action and expected outcome.

Stage one: Account creation and health questionnaire. Patients sign up online and complete a digital health assessment that covers medical history, current medications, weight history, and relevant health conditions. The accuracy of information provided at this stage directly affects the clinical evaluation that follows — all disclosures should be complete and accurate.

Stage two: Virtual clinician consultation. A licensed clinician reviews the submitted health information and conducts a virtual consultation. The clinician evaluates whether GLP-1 therapy may be appropriate based on the patient's profile. Eligibility criteria for GLP-1 medications typically include a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition — though the prescribing clinician makes the final determination based on the full clinical picture.

Stage three: Prescription and medication delivery. If the clinician determines a prescription is appropriate, the prescription is sent to a licensed U.S. pharmacy partner. Medication is then shipped directly to the patient's home. Delivery timelines depend on pharmacy processing and logistics.

Stage four: Ongoing support and monitoring. Wellorithm states that support is available 24 hours a day, seven days a week, by phone at +1 (877) 402-6778. Ongoing monitoring and plan adjustments are described as part of the program.

Medication Options Available Through Wellorithm

According to the official Wellorithm website, the platform offers four compounded medication pathways. All are prescription-only and subject to clinician approval.

Compounded Semaglutide Injection: A once-weekly injectable formulation using semaglutide as the active ingredient. Semaglutide is a GLP-1 receptor agonist that works by mimicking the GLP-1 hormone, which regulates appetite signaling, gastric emptying, and insulin secretion. Clinical trial data published in peer-reviewed literature — including the STEP trials — demonstrated meaningful weight reduction in adults with obesity when semaglutide was used alongside lifestyle interventions, though trial populations and conditions differ from real-world telehealth settings and individual outcomes vary.

Compounded Tirzepatide Injection: A once-weekly injectable formulation using tirzepatide, which acts on both GLP-1 and GIP receptors — a dual incretin mechanism. Published clinical trial data from the SURMOUNT trials showed pronounced average effects on body weight in certain trial populations; individual outcomes in real-world settings vary widely and are not designed to deliver.

Compounded Semaglutide Oral Dissolving Tablets: An oral alternative for patients for whom injectable formulations are not preferred, subject to clinician evaluation and prescribing appropriateness.

Compounded Tirzepatide Oral Dissolving Tablets: An oral alternative using tirzepatide, also subject to clinician evaluation.

None of these are manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards finished drug products. They are compounded formulations prepared by licensed pharmacies based on individual prescriptions. The clinician who evaluates your case will determine which option, if any, is appropriate for your health profile.

How GLP-1 Medications Work: The Mechanism

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone naturally released by the gastrointestinal tract in response to food intake. The mechanism involves several overlapping effects relevant to weight management.

GLP-1 receptors are found in the hypothalamus, a region of the brain involved in appetite regulation. Activation of these receptors reduces appetite signaling and increases satiety — the sense of fullness. GLP-1 also slows gastric emptying, meaning food moves more slowly from the stomach to the small intestine, which extends the physiological sense of fullness after a meal. On the metabolic side, GLP-1 stimulates insulin secretion in response to elevated blood glucose and suppresses glucagon, supporting glycemic control.

Tirzepatide adds a second mechanism: activation of GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP also plays a role in insulin secretion and has been studied for its effects on adipose tissue metabolism. The dual-receptor mechanism is the basis for the comparison between semaglutide and tirzepatide as weight management agents — a topic covered in depth in our Wellorithm semaglutide breakdown.

Who May Be Eligible

The published clinical guidelines for GLP-1 prescription weight management typically identify two primary eligibility criteria: a BMI of 30 or higher (classified as obesity), or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. These are the criteria reflected in FDA-registered, GMP-certified labeling for GLP-1 weight management medications and are the standard framework used by telehealth platforms operating in this space.

Wellorithm's FAQ states that eligibility is determined by the clinician following a medical evaluation. Prescription treatment is not designed to deliver. Certain medical conditions may disqualify a patient from GLP-1 therapy regardless of BMI, including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis. Complete and accurate disclosure during the intake process is essential for the clinician to make an appropriate assessment.

Pricing Structure

According to the official Wellorithm website, published starting prices are $147 for compounded semaglutide and $249 for compounded tirzepatide. Membership fees are billed on a recurring 28-day cycle. These are starting prices — actual costs depend on dosage and plan selected. Wellorithm's program operates on a cash-pay basis. Insurance is generally not billed directly; coverage or reimbursement depends on your individual plan. Always verify current pricing directly on the official website before enrolling, as pricing is subject to change.

What to Confirm Before You Enroll

Before committing to any telehealth GLP-1 program, the following questions are worth confirming directly with Wellorithm or with your own healthcare provider. Is the platform currently operating in your state — Wellorithm serves 49 states, with Louisiana currently excluded. What is the current pricing for the specific medication and dosage the clinician is likely to prescribe — starting prices reflect the lowest tier. What is the exact refund and cancellation policy — published terms state payments are non-refundable once processed, and cancellation is handled by contacting support via email. What pharmacy will dispense your medication, and what is that pharmacy's compounding compliance status. What follow-up and monitoring does the program include after the initial prescription.

For a complete evaluation of Wellorithm's program terms, pricing structure, and how it compares to similar platforms, see the full Wellorithm review and our weight management research hub.

Frequently Asked Questions

What is Wellorithm? Wellorithm is a telehealth weight management platform that connects eligible patients with licensed clinicians for evaluation and, when medically appropriate, prescription access to compounded GLP-1 medications such as semaglutide or tirzepatide. Compounded medications from this platform have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

How does the Wellorithm intake process work? Patients complete a brief online health questionnaire, connect with a licensed clinician via virtual consultation, and — if the clinician determines a prescription is appropriate — receive medication shipped from a licensed U.S. pharmacy. Eligibility is not designed to deliver.

What medications does Wellorithm offer? According to the official Wellorithm website, the platform offers compounded semaglutide injections, compounded tirzepatide injections, compounded semaglutide oral dissolving tablets, and compounded tirzepatide oral dissolving tablets. These are compounded formulations, not FDA-approved brand-name products.

Is Wellorithm available in all states? Per Wellorithm's published FAQ, the platform serves 49 U.S. states. Louisiana is currently excluded. Services are not available outside the United States.

Does Wellorithm accept insurance? According to Wellorithm's published terms, the program operates on a cash-pay basis. Insurance is generally not billed directly. Coverage or reimbursement, if any, depends on the individual plan — confirm with your insurer before enrolling.

By TotalCareMedical.com Health Team

Editorial notice: TotalCareMedical.com is an independent health and wellness research publication. This review is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation, prescription, and monitoring by a licensed healthcare professional. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Eligibility is determined by a licensed clinician. Some links on this page may be affiliate links — see our full disclosure for details. Pricing and program terms are based on publicly available information from the Wellorithm product page and are subject to change.

What Is Wellorithm?

Wellorithm is a telehealth weight management platform that connects patients with licensed U.S. clinicians for evaluation and, when a clinician determines it is medically appropriate, prescription access to compounded GLP-1 medications. The program operates through a three-entity structure standard across this category of service: Wellorithm is the technology platform, clinical decisions belong to independent licensed providers, and medications are dispensed by licensed U.S. pharmacy partners. These are three distinct functions operating under separate regulatory frameworks.

This review examines what Wellorithm actually offers — the verified medication options, the pricing and refund terms as published, the compounding distinction and regulatory context, the program structure, and what questions to confirm before enrolling. For a step-by-step explanation of how the platform process works, see our how Wellorithm works explainer. For a full breakdown of the semaglutide pathway specifically, see our Wellorithm semaglutide breakdown.

What Wellorithm Offers: Medication Options

According to the official Wellorithm website, the program offers four compounded medication pathways — all prescription-only and subject to clinician evaluation:

Compounded Semaglutide Injection: A once-weekly injectable formulation. Semaglutide is a GLP-1 receptor agonist — the active ingredient in FDA-approved brand-name products Wegovy and Ozempic. The compounded version is not an FDA-approved finished product.

Compounded Tirzepatide Injection: A once-weekly injectable formulation. Tirzepatide is a dual GLP-1/GIP receptor agonist — the active ingredient in FDA-approved Zepbound and Mounjaro. The compounded version is not an FDA-approved finished product.

Compounded Semaglutide Oral Dissolving Tablets: An oral formulation for patients for whom injectables are not preferred, subject to clinician evaluation.

Compounded Tirzepatide Oral Dissolving Tablets: An oral tirzepatide formulation, also subject to clinician evaluation and prescribing appropriateness.

As Wellorithm's own website states: compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. The prescribing clinician makes the determination of whether any of these options is appropriate for each individual patient based on their health profile and medical history.

Pricing: Verified Published Terms

According to the official Wellorithm website, published starting prices are as follows: compounded semaglutide starts at $147; compounded tirzepatide starts at $249.

These are starting prices. Actual costs depend on the dosage level prescribed and the specific plan selected. The program is billed on a recurring 28-day cycle. Wellorithm operates on a cash-pay model — insurance is generally not billed directly. Coverage or reimbursement, if any, depends on your individual insurance plan; confirm with your insurer before enrolling.

These figures were published on the official Wellorithm website at the time this review was prepared. Pricing is subject to change without notice. Always verify current pricing directly on the official Wellorithm website before making an enrollment decision.

Refund Policy: What the Published Terms Say

Per Wellorithm's published terms of service: membership payments are non-refundable once processed. Patients may cancel at any time by contacting the support team via email. There is no published unconditional money-back commitment. This is a meaningful distinction from some competitors in this space who publish conditional weight-loss is designed to deliver — Wellorithm's published terms do not include such a commitment as of the time this review was prepared.

Before enrolling in any recurring-billing subscription program, understanding the cancellation and refund terms is a basic consumer protection step. Verify the current published terms directly on the official Wellorithm website or with the support team before providing payment information.

The Compounding Distinction: What It Means

This is the most important concept to understand before evaluating any compounded GLP-1 telehealth program.

FDA-approved brand-name GLP-1 products — Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide) — are finished drug products that have undergone the FDA's comprehensive drug approval process: clinical trials, manufacturing quality standards, potency and stability testing, and ongoing post-market surveillance. They are produced by their respective pharmaceutical manufacturers under FDA oversight.

Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies based on individual patient prescriptions. The finished compounded products have not undergone the same FDA approval process. They contain the same active pharmaceutical ingredients as the brand-name drugs, but they are legally and regulatorily distinct products. Compounding pharmacies operate under state pharmacy law and applicable federal compounding statutes, which set different manufacturing standards than the FDA drug approval pathway.

Additionally, the legal framework for compounded GLP-1 medications in 2026 has been directly tied to FDA drug shortage designations — a regulatory context that has been actively evolving for both semaglutide and tirzepatide. Patients should confirm the current availability and regulatory standing of compounded GLP-1 medications through any specific platform before enrolling. This is not a static situation.

The Three-Entity Structure: Platform, Clinician, Pharmacy

Understanding how Wellorithm is organized clarifies what you are actually getting when you enroll. Wellorithm is the technology platform — it manages the intake process, connects patients with clinicians, coordinates with pharmacy partners, and provides the support infrastructure. The clinical decisions — including whether to prescribe, what to prescribe, and at what dose — belong to the independent licensed clinicians who conduct the evaluations. The medications are dispensed by licensed U.S. compounding pharmacies that are separate from both Wellorithm and the clinical providers.

This structure is standard across the telehealth weight management category and ensures appropriate legal separation between coordination, clinical decision-making, and medication dispensing. It also means that Wellorithm itself does not make prescribing decisions — those belong to the clinician who reviews your case.

Program Structure: What Wellorithm Describes

Wellorithm describes a four-stage process: a 2-minute online intake quiz to begin the approval process, a virtual consultation with a licensed clinician, a personalized plan and medication dispensed through a licensed pharmacy, and ongoing monitoring and support. The platform states that support is available 24 hours a day, seven days a week, by phone at +1 (877) 402-6778. Virtual consultations are conducted via video appointment scheduled to fit the patient's schedule, according to the official website.

GLP-1 medications require ongoing monitoring — dose titration, side effect assessment, and follow-up evaluation. A well-structured telehealth program includes these touchpoints rather than functioning as a one-time prescription service. Patients evaluating Wellorithm should confirm what follow-up is included in the program pricing and how ongoing monitoring is handled after the initial prescription.

Coverage: States Served

Per Wellorithm's published FAQ, the platform serves 49 U.S. states. Louisiana is currently excluded. Services are not available outside the United States. Confirm state availability directly with Wellorithm before beginning the intake process.

How Wellorithm Compares to the Category

The compounded GLP-1 telehealth space has expanded significantly heading into 2026. Wellorithm's published starting prices — $147 for semaglutide, $249 for tirzepatide — are at the lower end of published pricing for compounded GLP-1 programs in this category. For context, comparable platforms in the same category typically publish starting prices ranging from $147 to $350 or higher for compounded semaglutide, with tirzepatide programs generally priced higher than semaglutide across the category.

Price alone is not a reliable indicator of program quality. The relevant evaluation dimensions include: the clinical intake process and provider qualifications, the pharmacy sourcing and compounding compliance, what ongoing monitoring and follow-up are included, and the refund and cancellation terms. For a side-by-side evaluation of Wellorithm against other platforms in this category, see our Wellorithm vs. competitors comparison. For platform reviews of comparable services, see TeleHealth Med and SynergyRx GLP-1.

What to Confirm Before You Enroll

Before enrolling in Wellorithm or any compounded GLP-1 telehealth program, these are the questions worth confirming directly with the platform or your healthcare provider.

Is the specific compounded medication currently available in your state under the current regulatory framework? Is Wellorithm currently serving your state? What is the all-in pricing for the specific medication and dosage you are likely to be prescribed — the starting price reflects the lowest tier? What pharmacy will dispense the medication, and what is that pharmacy's compounding compliance status? What monitoring and follow-up is included after the initial prescription, and is that covered in the published price? What are the exact cancellation and refund terms currently in effect?

For a full breakdown of potential side effects and safety considerations, see our Wellorithm side effects breakdown. For a full overview of how the program process works from intake to delivery, see our how Wellorithm works explainer. For a complete index of GLP-1 telehealth platform reviews on this site, visit our telehealth platform reviews hub.

Frequently Asked Questions

Is Wellorithm a legitimate telehealth service? Wellorithm is a telehealth platform that connects patients with licensed U.S. clinicians and licensed pharmacy partners for compounded GLP-1 evaluation and, when prescribed, medication delivery. The medications offered are compounded formulations that have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Whether the platform is appropriate for a specific individual depends on clinical factors evaluated by a licensed provider.

How much does Wellorithm cost? According to the official Wellorithm website, compounded semaglutide starts at $147 and compounded tirzepatide starts at $249. These are starting prices — actual costs depend on dosage and plan. Membership is billed on a recurring 28-day cycle. Payments are non-refundable once processed. Verify current pricing directly on the official website before enrolling.

Does Wellorithm offer a money-back guarantee? Per Wellorithm's published terms, membership payments are non-refundable once processed. Patients can cancel at any time by contacting the support team via email. There is no published unconditional money-back commitment. Verify current refund terms directly with Wellorithm before enrolling.

What states does Wellorithm serve? Per Wellorithm's published FAQ, the platform serves 49 U.S. states. Louisiana is currently excluded. Services are not available outside the United States. Confirm state availability directly with Wellorithm before enrolling.

What is the difference between compounded and brand-name GLP-1 medications? FDA-approved brand-name GLP-1 products — such as Wegovy and Ozempic (semaglutide) and Zepbound and Mounjaro (tirzepatide) — have been reviewed by the FDA for safety, efficacy, and manufacturing quality as finished products. Compounded GLP-1 medications are prepared by licensed pharmacies based on individual prescriptions and have not undergone the same FDA approval process. Both contain the same active ingredients, but their regulatory status and manufacturing quality standards differ.

How do I contact Wellorithm? Per the official Wellorithm website, the support team is available 24 hours a day, seven days a week, by phone at +1 (877) 402-6778 and by email at contact@wellorithm.com.